Table 4.
No. | Study | Methods | Participants | Interventions | Outcomes | Results |
---|---|---|---|---|---|---|
1 | Nagata et al. [100] | 12 weeks, parallel, double-blind, randomised | 36 completing out of 36 | 5% KNO3 versus 0% KNO3 | Tactile, air blast, and subjective | 5% KNO3 > control (P, 0.05) at 4, 8, and 12 weeks |
2 | Schiff et al. [101] | 12 weeks, parallel, double-blind, randomised | 58 completing out of 67 | 5% KNO3 and 0.243% sodium MFP versus 0% KNO3 and 0.243% sodium MFP | Thermal, tactile, air blast, and subjective | Test > control (P < 0.01) at 6 and 12 weeks |
3 | Schiff et al. [102] | 8 weeks, parallel, double-blind, randomised | 39 completing out of 48 | 5% KNO3 and 1500 ppm MFP versus 0% KNO3 and 1500 ppm MFP | Tactile and air blast | 5% KNO3 > control (P < 0.0001) at 4 and 8 weeks |
4 | Schiff et al. [103] | 8 weeks, parallel, double-blind, randomised | 80 participants | 5% KNO3 and 0.243% NaF versus 0.243% NaF | Tactile and air blast | 5% KNO3 > positive and negative controls (P < 0.05) in tactile and air blast sensitivity, at 4 and 8 weeks |
5 | Silverman et al. [104] | 8 weeks, parallel, double-blind, randomised | 110 completing | 5% KNO3 versus 0% KNO3 | Tactile, cold air, and subjective | 5% KNO3 > +/− F > F control at 4 and 8 weeks (P < 0.02); NS between 10% Sr Cl2 and control; 5% KNO3 > +/− F > 10% Sr Cl2 at 8 weeks (P < 0.05) |
6 | Sowinski et al. [105]* | 8 weeks, parallel, double-blind, randomised | 67 completing | 5% KNO3 and 0.243% NaF versus 0.243% NaF | Tactile and air blast | KNO3 > control significant improvements in tactile and air blast at 4 and 8 weeks |
*Product withdrawn from the market.